Hepatitis A impairs the function of human hepatic CYP2A6 in vivo.

[1]  F. Chisari,et al.  Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis , 1996, Hepatology.

[2]  P. Honkakoski,et al.  Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine , 1996, Hepatology.

[3]  A. Poso,et al.  Competitive inhibition of coumarin 7‐hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP2A6 , 1995, British journal of pharmacology.

[4]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[5]  E. Alhava,et al.  The inhibition of CYP enzymes in mouse and human liver by pilocarpine , 1995, British journal of pharmacology.

[6]  C. McClain,et al.  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. , 1994, The Journal of clinical investigation.

[7]  O. Pelkonen,et al.  Modification of hepatic cytochrome P450 profile by cocaine-induced hepatotoxicity in DBA/2 mouse. , 1994, European journal of pharmacology.

[8]  C. Wild,et al.  Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome p450 and carcinogen metabolism in male hamster liver1,2 , 1994, Molecular carcinogenesis.

[9]  J. Hakkola,et al.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. , 1994, Biochemical pharmacology.

[10]  H. Sigusch,et al.  Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. , 1993, Biochemical pharmacology.

[11]  O. Pelkonen,et al.  Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse. , 1993, Biochemical pharmacology.

[12]  L. Bertilsson,et al.  Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. , 1993, Pharmacology & toxicology.

[13]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[14]  J. Idle,et al.  Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. , 1992, Journal of chromatography.

[15]  P. Thomas,et al.  Evidence from dwarf rats that growth hormone may not regulate the sexual differentiation of liver cytochrome P450 enzymes and steroid 5 alpha-reductase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Morgan,et al.  Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. , 1991, Molecular pharmacology.

[17]  L. Rossi,et al.  Regulation of the expression of the sex-specific isoforms of cytochrome P-450 in rat liver. , 1991, European journal of biochemistry.

[18]  K. Renton,et al.  Regulation of hepatic cytochrome P-450 during infectious disease. , 1990, Canadian journal of physiology and pharmacology.

[19]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[20]  D. Waxman,et al.  Gene conversion and differential regulation in the rat P-450 IIA gene subfamily. Purification, catalytic activity, cDNA and deduced amino acid sequence, and regulation of an adult male-specific hepatic testosterone 15 alpha-hydroxylase. , 1988, The Journal of biological chemistry.

[21]  M. Lang,et al.  Pyrazole as a modifier of liver microsomal monooxygenase in DBA/2N and AKR/J mice. , 1987, Biochemical pharmacology.

[22]  L. Powell,et al.  Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. , 1978, Gastroenterology.

[23]  P. Meffin,et al.  Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green , 1976, Clinical pharmacology and therapeutics.

[24]  D. Tuma,et al.  Altered elimination of antipyrine in patients with acute viral hepatitis. , 1976, Gut.

[25]  O. Pelkonen,et al.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. , 1995, British journal of clinical pharmacology.

[26]  E. Lee,et al.  The effects of an interferon inducer, polyriboinosinic polyribocytidylic acid on cytochrome P-450 dependent hepatic progesterone metabolism. , 1993, Life sciences.

[27]  M. J. Phillips,et al.  Pathogenesis of Liver Diseases , 1987 .

[28]  A. Cohen.  Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. , 1979, Food and cosmetics toxicology.